Radiopharm Theranostics director discloses holdings
Radiopharm Theranostics Ltd director Paul Hopper has filed an initial Form 3 listing his ownership in Ordinary Shares and options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd director Paul Hopper has filed an initial Form 3 listing his ownership in Ordinary Shares and options. The filing shows direct ownership of 53,900,000 Ordinary Shares, plus additional indirect holdings through Kilinwata Investments Pty Ltd and his spouse. It also details multiple Option (right to buy) positions over Ordinary Shares with exercise prices between 0.0250 and 0.2000 and expirations ranging from 2026 to 2030, including grants that vest only if he remains a Director on specified future dates.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
HOPPER PAUL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 53,642,000 contracts (Direct);
Option (right to buy) — 7,781,757 contracts (Indirect, Held through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director);
Ordinary Shares — 53,900,000 shares (Direct);
Ordinary Shares — 250,000 shares (Indirect, Held by Deborah Coleman, who is Mr. Hopper's spouse.);
Ordinary Shares — 93,571,428 shares (Indirect, Held through Kilinwata Investments Pty Ltd, of which Mr. Hopper is the sole Shareholder and Director)
Footnotes (1)
- F1. Granted on December 16, 2024. 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027 provided that Mr. Hopper is still a Director on such dates.
Key Figures
Direct Ordinary Shares: 53,900,000 shares
Indirect shares via Kilinwata: 93,571,428 shares
Indirect shares via spouse: 250,000 shares
+5 more
8 metrics
Direct Ordinary Shares
53,900,000 shares
Total shares held directly by Paul Hopper following the reported holdings
Indirect shares via Kilinwata
93,571,428 shares
Ordinary Shares held through Kilinwata Investments Pty Ltd as of the reported date
Indirect shares via spouse
250,000 shares
Ordinary Shares held by Deborah Coleman, Mr. Hopper’s spouse
Option at 0.2000 exercise price
3,571,428 underlying shares
Indirect Option (right to buy) over Ordinary Shares, expiring on 2026-11-30
Option at 0.0600 exercise price
27,500,000 underlying shares
Direct Option (right to buy) over Ordinary Shares, expiring on 2026-08-24
Long-dated options at 0.0250
6,048,542 underlying shares
Direct Option (right to buy) over Ordinary Shares, expiring on 2030-07-01
Option grant vesting 2026-09-30
2,666,667 options
Options vest on 2026-09-30 if Mr. Hopper remains a Director
Option grant vesting 2027-09-30
2,666,666 options
Options vest on 2027-09-30 subject to continued service as Director
Key Terms
Ordinary Shares, Option (right to buy), exercise price, expiration date, +1 more
5 terms
Option (right to buy) financial
"security_title": "Option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "0.0600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2030-07-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"options will vest on September 30, 2026 and 2,666,666 options will vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Paul Hopper’s Form 3 for Radiopharm Theranostics (RADX) disclose?
The Form 3 discloses Paul Hopper’s initial ownership in Ordinary Shares and stock options of Radiopharm Theranostics. It lists large direct and indirect share positions plus several option grants with specified exercise prices, vesting schedules, and expiration dates.
How are Paul Hopper’s indirect Radiopharm Theranostics (RADX) holdings structured?
Indirect holdings are reported as Ordinary Shares and options held through Kilinwata Investments Pty Ltd, where he is sole shareholder and director, and shares held by his spouse. The filing attributes these positions as indirect beneficial ownership for disclosure purposes.
What does the footnote in Paul Hopper’s Radiopharm Theranostics (RADX) Form 3 explain?
The footnote explains an option grant on December 16, 2024. It states 2,666,667 options will vest on September 30, 2026 and 2,666,666 options on September 30, 2027, provided Mr. Hopper remains a Director on those dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates